Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2018 09:00 ET | Source: Processa Pharmaceuticals, Inc.

PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS

HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been...